| Cat.No. | Name | Information |
|---|---|---|
| M14738 | NCT-502 | NCT-502 is a human phosphoglycerate dehydrogenase (PHGDH) inhibitor, cytotoxic to PHGDH-dependent cancer cells, and reduces glucose-derived serine production, with an IC50 of 3.7 μM against PHGDH. |
| M14661 | BI-4924 | BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal, as well as hepatocytic stability. |
| M14660 | BI-4916 | BI-4916 is a prodrug of BI-4924. BI-4924 is a NADH/NAD+-competitive PHGDH inhibitor. |
| M8604 | NCT-503 | NCT-503 is an inhibitor of phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first, rate-limiting step of glucose-derived serine synthesis. |
| M6566 | CBR 5884 | CBR 5884 is a 3-Phosphoglycerate dehydrogenase (PHGDH) inhibitor. |
| M29874 | PKUMDL-WQ-2101 | PKUMDL-WQ-2101 is a non-NAD+-competing allosteric phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity. |
| M29015 | PHGDH-inactive | PHGDH-inactive has no activity against PHGDH and serves as a negative control of NCT-502 and NCT-503. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
